A citation-based method for searching scientific literature

Jixin Zhong, Xiaoquan Rao, Sanjay Rajagopalan. Atherosclerosis 2013
Times Cited: 151







List of co-cited articles
730 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome.
Daniela Lamers, Susanne Famulla, Nina Wronkowitz, Sonja Hartwig, Stefan Lehr, D Margriet Ouwens, Kristin Eckardt, Jean M Kaufman, Mikael Ryden, Stefan Müller,[...]. Diabetes 2011
384
29

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
27

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
Jennifer B Green, M Angelyn Bethel, Paul W Armstrong, John B Buse, Samuel S Engel, Jyotsna Garg, Robert Josse, Keith D Kaufman, Joerg Koglin, Scott Korn,[...]. N Engl J Med 2015
24

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
20

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Zubair Shah, Thomas Kampfrath, Jeffrey A Deiuliis, Jixin Zhong, Colleen Pineda, Zhekang Ying, Xiaohua Xu, Bo Lu, Susan Moffatt-Bruce, Rekha Durairaj,[...]. Circulation 2011
269
16

A potential role for dendritic cell/macrophage-expressing DPP4 in obesity-induced visceral inflammation.
Jixin Zhong, Xiaoquan Rao, Jeffrey Deiuliis, Zachary Braunstein, Vimal Narula, Jeffrey Hazey, Dean Mikami, Bradley Needleman, Abhay R Satoskar, Sanjay Rajagopalan. Diabetes 2013
115
15

DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
Jixin Zhong, Andrei Maiseyeu, Stephen N Davis, Sanjay Rajagopalan. Circ Res 2015
120
14


A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,[...]. J Am Coll Cardiol 2012
209
13


Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Gian Paolo Fadini, Angelo Avogaro. Vascul Pharmacol 2011
160
12

Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro.
Henrike Sell, Matthias Blüher, Nora Klöting, Raphaela Schlich, Miriam Willems, Florian Ruppe, Wolfram Trudo Knoefel, Arne Dietrich, Barbara A Fielding, Peter Arner,[...]. Diabetes Care 2013
136
12

Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl-peptidase 4 inhibition.
Swenja Kröller-Schön, Maike Knorr, Michael Hausding, Matthias Oelze, Alexandra Schuff, Richard Schell, Stephan Sudowe, Alexander Scholz, Steffen Daub, Susanne Karbach,[...]. Cardiovasc Res 2012
130
11


Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
628
11

Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice.
Meghan Sauvé, Kiwon Ban, M Abdul Momen, Yu-Qing Zhou, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2010
219
10

Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions.
Toshimasa Shigeta, Morihiko Aoyama, Yasuko K Bando, Akio Monji, Toko Mitsui, Miwa Takatsu, Xiang-Wu Cheng, Takahiro Okumura, Akihiro Hirashiki, Kohzo Nagata,[...]. Circulation 2012
132
10

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.
Faiez Zannad, Christopher P Cannon, William C Cushman, George L Bakris, Venu Menon, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer, Craig Wilson,[...]. Lancet 2015
488
10

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
10


Direct association of adenosine deaminase with a T cell activation antigen, CD26.
J Kameoka, T Tanaka, Y Nojima, S F Schlossman, C Morimoto. Science 1993
437
9

Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26.
D Marguet, L Baggio, T Kobayashi, A M Bernard, M Pierres, P F Nielsen, U Ribel, T Watanabe, D J Drucker, N Wagtmann. Proc Natl Acad Sci U S A 2000
408
9

Cardiovascular biology of the incretin system.
John R Ussher, Daniel J Drucker. Endocr Rev 2012
365
9

Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?
Roger Yazbeck, Gordon S Howarth, Catherine A Abbott. Trends Pharmacol Sci 2009
182
9

Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetes.
Junichi Matsubara, Seigo Sugiyama, Eiichi Akiyama, Satomi Iwashita, Hirofumi Kurokawa, Keisuke Ohba, Hirofumi Maeda, Koichiro Fujisue, Eiichiro Yamamoto, Koichi Kaikita,[...]. Circ J 2013
147
9

Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.
Nasib Ervinna, Tomoya Mita, Eisuke Yasunari, Kosuke Azuma, Rica Tanaka, Satoshi Fujimura, Dewi Sukmawati, Takashi Nomiyama, Akio Kanazawa, Ryuzo Kawamori,[...]. Endocrinology 2013
125
9

DPP4 in Diabetes.
Diana Röhrborn, Nina Wronkowitz, Juergen Eckel. Front Immunol 2015
188
9

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways.
Zubair Shah, Colleen Pineda, Thomas Kampfrath, Andrei Maiseyeu, Zhekang Ying, Ira Racoma, Jeffrey Deiuliis, Xiaohua Xu, Qinghua Sun, Susan Moffatt-Bruce,[...]. Vascul Pharmacol 2011
119
9

Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Keizo Kanasaki, Sen Shi, Megumi Kanasaki, Jianhua He, Takako Nagai, Yuka Nakamura, Yasuhito Ishigaki, Munehiro Kitada, Swayam Prakash Srivastava, Daisuke Koya. Diabetes 2014
224
9

Soluble CD26/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate/insulin-like growth factor II receptor.
Hideto Ikushima, Yasuhiko Munakata, Satoshi Iwata, Kei Ohnuma, Seiji Kobayashi, Nam H Dang, Chikao Morimoto. Cell Immunol 2002
62
12

Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.
Leonardo dos Santos, Thiago A Salles, Daniel F Arruda-Junior, Luciene C G Campos, Alexandre C Pereira, Ana Luiza T Barreto, Ednei L Antonio, Alfredo J Mansur, Paulo J F Tucci, José E Krieger,[...]. Circ Heart Fail 2013
85
9

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
F Vittone, A Liberman, D Vasic, R Ostertag, M Esser, D Walcher, A Ludwig, N Marx, M Burgmaier. Diabetologia 2012
76
10

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
407
8

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
8


Increased hepatic expression of dipeptidyl peptidase-4 in non-alcoholic fatty liver disease and its association with insulin resistance and glucose metabolism.
Masayuki Miyazaki, Masaki Kato, Kosuke Tanaka, Masatake Tanaka, Motoyuki Kohjima, Kazuhiko Nakamura, Munechika Enjoji, Makoto Nakamuta, Kazuhiro Kotoh, Ryoichi Takayanagi. Mol Med Rep 2012
98
8

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Wei Jing Liu, Shu Hua Xie, Yu Ning Liu, Won Kim, Heung Yong Jin, Sung Kwang Park, Yi Ming Shao, Tae Sun Park. J Pharmacol Exp Ther 2012
164
8

Serum dipeptidyl peptidase-4 activity in insulin resistant patients with non-alcoholic fatty liver disease: a novel liver disease biomarker.
Gábor Firneisz, Tímea Varga, Gabriella Lengyel, János Fehér, Dóra Ghyczy, Barna Wichmann, László Selmeci, Zsolt Tulassay, Károly Rácz, Anikó Somogyi. PLoS One 2010
94
8

Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus.
E Mannucci, L Pala, S Ciani, G Bardini, A Pezzatini, I Sposato, F Cremasco, A Ognibene, C M Rotella. Diabetologia 2005
159
8

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
734
7

Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2.
Nina Wronkowitz, Sven W Görgens, Tania Romacho, Laura A Villalobos, Carlos F Sánchez-Ferrer, Concepción Peiró, Henrike Sell, Jürgen Eckel. Biochim Biophys Acta 2014
92
7


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
7

Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
C Klemann, L Wagner, M Stephan, S von Hörsten. Clin Exp Immunol 2016
187
7

Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
7

Dipeptidyl peptidase-4: a key player in chronic liver disease.
Minoru Itou, Takumi Kawaguchi, Eitaro Taniguchi, Michio Sata. World J Gastroenterol 2013
112
6



DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.
Nga N Ta, Corinne A Schuyler, Yanchun Li, Maria F Lopes-Virella, Yan Huang. J Cardiovasc Pharmacol 2011
121
6

Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.
Jixin Zhong, Quan Gong, Aditya Goud, Srividya Srinivasamaharaj, Sanjay Rajagopalan. J Diabetes Res 2015
38
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.